- Home
- ARVN vs NFBK Comparison
ARVN vs NFBK Comparison
Compare ARVN & NFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARVN | NFBK |
|---|---|---|
| Founded | 2015 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 591.4M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ARVN | NFBK |
|---|---|---|
| Price | $10.04 | $14.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 3 |
| Target Price | ★ $15.05 | $13.50 |
| AVG Volume (30 Days) | ★ 640.4K | 182.5K |
| Earning Date | 05-04-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 3.73% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $262,600,000.00 | $6,870,000.00 |
| Revenue This Year | N/A | $4.95 |
| Revenue Next Year | N/A | $6.32 |
| P/E Ratio | ★ N/A | $702.75 |
| Revenue Growth | N/A | ★ 6.84 |
| 52 Week Low | $5.90 | $9.91 |
| 52 Week High | $14.22 | $14.21 |
Technical Indicators
Market Signals| Indicator | ARVN | NFBK |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 56.68 |
| Support Level | $9.96 | $13.52 |
| Resistance Level | $10.18 | $14.09 |
| Average True Range (ATR) | 0.55 | 0.20 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 20.36 | 75.54 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union, and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.